Clinical efficiency of antioxidant therapy in patients with liver cirrhosis and acute blood loss

Objective: to determine the clinical efficiency of antioxidant therapy in patients with liver cirrhosis and acute blood loss.

Material and methods. The study included 286 patients with liver cirrhosis and acute blood loss of varying degrees of severity. The patients were divided into two series of studies. In the first series, the patients received the therapy according to the clinical diagnostic and treatment protocols, in the second series 1 according to the same protocols in combination with an intravenous administration of the antioxidant complexes “Reamberin” and “Fluimucil”. After 48 hours from admission, the antioxidant status of blood serum, the blebbing index of lymphocytes, the concentration of uric acid, and the level of hemoglobin were analyzed. The indicators of the clinical efficiency of the treatment were determined: risk of absolute mortality, risk of relative mortality, the number needed to treat.

Results. The blood serum of the patients from the first series of studies was characterized by pronounced prooxidant activity, high values of the lymphocyte blebbing index, and a small amount of uric acid, which was indicative of the development of oxidative stress. The mortality rate in this series of studies was 26.0 %. The patients of the second series of studies were characterized by pronounced antioxidant activity of blood serum, low values of the lymphocyte blebbing index, and high concentrations of uric acid, which indicated a decrease in the activity of systemic oxidation processes. The mortality rate in this series of studies was 18.2 %. The duration of the treatment decreased from 16.5 days (first series) to 13.0 days (second series).

Conclusion. The combined use of the “Reamberin” and “Fluimucil” complexes as part of the therapy according to the clinical diagnostic and treatment protocols leads to a relief of oxidative stress in patients with liver cirrhosis complicated by acute blood loss. The blood serum of these patients is characterized by pronounced antioxidant activity, low values of the lymphocyte blebbing index, and a high concentration of uric acid, which reduces the risk for the development of multiple organ failure syndrome. This therapy decreases the mortality rate to 18.2 % and the duration of the treatment to 13.0 days.

1. Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014 Jul 7;20(25):8082-91. https://doi.org/10.3748/wjg.v20.i25.8082

2. Garelik PV. Mogilevets EV. Khirurgicheskie aspekty korrektsii portal'noy gipertenzii: monografiya. Grodno, Belarus': GrGMU; 2015. 327 p. (In Russ.). http://elib.grsmu.by/handle/files/144

3. Zyblev SL, Dundarov ZA. Primenenie antioksidantov pri ostrom gastroduodenal'nom jazvennom krovotechenii. Novosti Hirurgii. 2014;22(2):155–63. (in Russ.) https://

4. doi.org/10.18484/2305-0047.2014.2.155

5. Vinichuk SM. Okislitel'nyj stress pri ostrom ishemicheskom insul'te i ego korrekcija s ispol'zovaniem antioksidanta meksidola. Mezhdunarodnyj Nevrologicheskij Zhurnal. 2006;1:79–85. (in Russ.)

6. Zyblev SL, Dundarov ZA, Gricuk AI. Rol' mochevoj kisloty v sisteme antioksidantnoj zashhity organizma. Health and Ecology Iissues. 2016;(1):50-55. (in Russ.)

7. Shherba AE, Korotkov SV, Minov AF, Slobodin JuV. Vlijanie sevofljurana i acetilcisteina na ishemicheskireperfuzionnoe povrezhdenie pecheni donora so smert'ju mozga. Vestnik Transplantologii i Iskusstvennyh Organov. 2013;15(1):39–44. (in Russ.)

8. Zarivchackij MF, Kamenskih ED, Mugaratov IN. Ocenka jeffektivnosti primenenija remaksola u bol'nyh cirrozom pecheni. Hirurgija. 2013;3:79–82. (in Russ.)

9. Balasubramaniyan V. Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress. World Journal of Hepatology. 2015;7(3):443–59. https://doi.org/ 10.4254 / wjh.v7.i3.443

10. Zyblev SL, Dundarov ZA. Primenenie antioksidantov pri ostrom gastroduodenal'nom jazvennom krovotechenii. Novosti Hirurgii. 2014;22(2):155–63. (In Russ.). http://dx.doi.org/10.18484/2305-0047.2014.2.155|

11. Zyblev SL, Dundarov ZA, Gricuk AI. Sostojanie antioksidantnoj aktivnosti krovi pri gemorragicheskom shoke v jeksperimente. Health and Ecology Issues. 2013;(2)93–97. (in Russ.)

12. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009 Jan 1;417(1):1-13. https://doi.org/10.1042/BJ20081386

13. Kondrat'eva TS. Babinceva AJu. Ocenka blebbing-fenomena kak metoda diagnostiki stepeni tjazhesti diabeticheskoj polinejropatii. Vestnik Soveta Molodyh Uchjonyh i Specialistov Cheljabinskoj Oblasti. 2018;3(22):98–102. (in Russ.)

14. Vlasov AP, Trofimov VA, Vlasova TI, Myshkina NA. Sistemnyj membranodestabilizirujushhij distresssindrom v hirurgii: ponjatie, patogenez, diagnostika. Hirurgija. 2019;5:25–30. (in Russ.)

15. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2016;1863(12):2977–92.

16. Moroz VV, Salmina AB, Fursov AA, Mihutkina SV. Novye aspekty razvitija sistemnoj vospalitel'noj reakcii posle aortokoronarnogo shuntirovanija. Obshhaja Reanimatologija. 2008;4:5–8. (in Russ.)

17. Kosinec VA. Primenenie reamberina v korrekcii funkcional'noj aktivnosti jenterocitov pri jeksperimental'nom gnojnom peritonite. Jeksperimental'naja i Klinicheskaja Farmakologija. 2010;73(2):35–38. (in Russ.)

18. Zhukova VJu. Jeffektivnost' dinamicheskoj jelektronejrostimuljacii u sportsmenov s travmami oporno-dvigatel'nogo apparata. Voprosy Sovremennoj Pediatrii. 2014;13(4):131–35. (in Russ.)